However, IDH-mutant WHO grade II and III astrocytomas were associated with a better OS than their IDH wild-type counterparts, and, strikingly, IDH wild-type WHO grade II and III had a worse survival than IDH-mutant GBM. This evidence concerns the gene IDH2 and glioblastoma.